China Securities Co.,Ltd. issued a research report on July 12th, recommending keeping confidence in the pharmaceutical industry in the second half of the year and waiting for the right time. We are bullish on the following: 1) Prescription drugs continue to grow, driven by innovation and access, with intensive catalysts expected through 2024. We are bullish on innovative drugs and high-quality companies combining innovative and generic drugs. 2) We are optimistic about the gradual recovery of the medical device sector in the second half of the year. 3) We expect improvement in growth rate of the traditional Chinese medicine sector in the second half of the year, and are confident in industry leaders. 4) We are optimistic about high-quality targets in state-owned enterprise reform. 5) There are structural opportunities in the active pharmaceutical ingredient industry. 6) We are bullish on the leading innovative drug and medical device companies in the overseas market.
中信建投：对于下半年医药板块建议保持信心，等待时机
China Securities Co.,Ltd.: We recommend keeping confidence in the pharmaceutical industry in the second half of the year, waiting for the right time.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.